BRITNEY SKILLMAN: Open Payments
NPI 1003489261 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$501 in 18 payments from 6 companies in 2025. Trend: 2023 $176 · 2024 $149 · 2025 $501
Food & beverage: $501
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 8 | $189 |
| E.R. Squibb & Sons, L.L.C. | 1 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Teva Pharmaceuticals USA, Inc. | 2 | $60 |
| Alkermes, Inc. | 2 | $44 |
| Janssen Pharmaceuticals, Inc | 1 | $28 |
Products named: INGREZZA, COBENFY, UZEDY, ARISTADA, ABILIFY ASIMTUFII, INVEGA SUSTENNA, ABILIFY MAINTENA, REXULTI.
Industry payments across WA — which companies pay providers there.
